Indeed, the correlations between CD4+CTLA-4+ T cells and Treg subgroups in circulation of patients with advanced stages could lead to the inhibition of antitumor immunity, which results in a negative outcome in patients with CRC. The gene discussed is CTLA4; the disease is colorectal carcinoma.